Landmark Medical center: drugs
Schedule G of this filing lists 58 drugs, with an amount and a number of claims for each, as filed. Every amount links to its page of the filing.
The schedule's total is printed as “Total Costs of Prescription Drugs Obtained Through 340B Program Claimed for Reimbursement”. The filings describe the amounts in more than one way. Methods says more.
- 58drugs listed
- $5,743,276.33 (Schedule G, printed total, page 13 of the filing PDF)Total as filed
- 29,401 (Schedule G, printed claims total, page 13 of the filing PDF)Claims total as filed
- 9rows show “fewer than 6” for claims. What this means
All 58 drug rows
| Line | Drug | Amount as filed | Claims as filed |
|---|---|---|---|
| 1 | Keytruda 100 mg/4 mL SOLN00006302602Listed by the FDA as Keytrudapembrolizumab25 mg/mLinjection, solutionMerck Sharp & Dohme LLC | 1,078,787.86 (Schedule G, line 1, page 11 of the filing PDF) | 66 |
| 2 | Tecentriq 1,200 mg/20 mL SOLN50242091701Listed by the FDA as Tecentriqatezolizumab1,200 mg/20 mLinjection, solutionGenentech, Inc. | 478,405.44 (Schedule G, line 2, page 11 of the filing PDF) | 41 |
| 3 | Darzalex Faspro 1,800-30,000 mg-UT/15 mL SOLN57894050301Listed by the FDA as Darzalex Fasprodaratumumab and hyaluronidase-fihj (human recombinant)1,800 mg/15 mL; 30,000 units/15 mLinjectionJanssen Biotech, Inc. | 435,845.02 (Schedule G, line 3, page 11 of the filing PDF) | 39 |
| 4 | Opdivo 240 mg/24 mL SOLN00003373413Listed by the FDA as Opdivonivolumab10 mg/mLinjectionE.R. Squibb & Sons, L.L.C. | 404,055.36 (Schedule G, line 4, page 11 of the filing PDF) | 31 |
| 5 | Imfinzi 500 mg/10 mL SOLN00310461150Listed by the FDA as Imfinzidurvalumab500 mg/10 mLinjection, solutionAstraZeneca Pharmaceuticals LP | 399,610.38 (Schedule G, line 5, page 11 of the filing PDF) | 48 |
| 6 | Opdualag 240-80 mg/20 mL SOLN00003712511Listed by the FDA as Opdualagnivolumab and relatlimab-rmbw12 mg/mL; 4 mg/mLinjectionE.R. Squibb & Sons, L.L.C. | 250,084.10 (Schedule G, line 6, page 11 of the filing PDF) | 11 |
| 7 | Yervoy 50 mg/10 mL SOLN00003232711Listed by the FDA as Yervoyipilimumab5 mg/mLinjectionE.R. Squibb & Sons, L.L.C. | 229,513.07 (Schedule G, line 7, page 11 of the filing PDF) | 17 |
| 8 | Enhertu 100 mg SOLR65597040601Listed by the FDA as Enhertufam-trastuzumab deruxtecan-nxki100 mg/5 mLinjection, powder, lyophilized, for solutionDaiichi Sankyo Inc. | 174,837.16 (Schedule G, line 8, page 11 of the filing PDF) | 19 |
| 9 | Reblozyl 75 mg SOLR59572077501Listed by the FDA as Reblozylluspatercept75 mginjection, powder, lyophilized, for solutionCelgene Corporation | 163,969.50 (Schedule G, line 9, page 11 of the filing PDF) | 12 |
| 10 | Gamunex-C 20 g/200 mL SOLN13533080024Listed by the FDA as Gamunex-Cimmune globulin (human)10 g/100 mLinjectionGrifols USA, LLC | 150,080.52 (Schedule G, line 10, page 11 of the filing PDF) | 39 |
| 11 | Polivy 140 mg SOLR50242010501Listed by the FDA as Polivypolatuzumab vedotin140 mg/7.52 mLinjection, powder, lyophilized, for solutionGenentech, Inc. | 124,042.24 (Schedule G, line 11, page 11 of the filing PDF) | 8 |
| 12 | Zepzelca 4 mg SOLR68727071201Listed by the FDA as Zepzelcalurbinectedin0.5 mg/mLinjection, powder, lyophilized, for solutionJazz Pharmaceuticals, Inc. | 107,619.78 (Schedule G, line 12, page 11 of the filing PDF) | 10 |
| 13 | Ocrevus 300 mg/10 mL SOLN50242015001Listed by the FDA as Ocrevusocrelizumab300 mg/10 mLinjectionGenentech, Inc. | 103,916.83 (Schedule G, line 13, page 11 of the filing PDF) | fewer than 6 (the count is not shown) |
| 14 | Gazyva 1,000 mg/40 mL SOLN50242007001Listed by the FDA as Gazyvaobinutuzumab1,000 mg/40 mLinjection, solution, concentrateGenentech, Inc. | 100,738.13 (Schedule G, line 14, page 11 of the filing PDF) | 15 |
| 15 | Sylvant 400 mg SOLR73090042101Listed by the FDA as Sylvantsiltuximab400 mginjection, powder, for solutionRecordati Rare Diseases, Inc. | 95,644.92 (Schedule G, line 15, page 11 of the filing PDF) | 8 |
| 16 | Imjudo 300 mg/15 mL SOLN00310453530Listed by the FDA as Imjudotremelimumab300 mg/15 mLinjection, solutionAstraZeneca Pharmaceuticals LP | 91,273.56 (Schedule G, line 16, page 11 of the filing PDF) | fewer than 6 (the count is not shown) |
| 17 | Tecentriq 840 mg/14 mL SOLN50242091801Listed by the FDA as Tecentriqatezolizumab840 mg/14 mLinjection, solutionGenentech, Inc. | 89,155.50 (Schedule G, line 17, page 12 of the filing PDF) | 8 |
| 18 | Kyprolis 60 mg SOLR76075010101Listed by the FDA as Kyproliscarfilzomib60 mg/30 mLinjection, powder, lyophilized, for solutionOnyx Pharmaceuticals, Inc. | 76,134.36 (Schedule G, line 18, page 12 of the filing PDF) | 27 |
| 19 | Mvasi 400 mg/16 mL SOLN55513020701Listed by the FDA as Mvasibevacizumab-awwb400 mg/16 mLinjection, solutionAmgen, Inc | 75,387.36 (Schedule G, line 19, page 12 of the filing PDF) | 43 |
| 20 | Cyramza 500 mg/50 mL SOLN00002767801Listed by the FDA as Cyramzaramucirumab10 mg/mLsolutionEli Lilly and Company | 71,719.46 (Schedule G, line 20, page 12 of the filing PDF) | 11 |
| 21 | Xgeva 120 mg/1.7 mL SOLN55513073001Listed by the FDA as Xgevadenosumab120 mg/1.7 mLinjectionAmgen, Inc | 67,831.80 (Schedule G, line 21, page 12 of the filing PDF) | 33 |
| 22 | Venofer 20 mg/mL SOLN00517231005Listed by the FDA as Venoferiron sucrose20 mg/mLinjection, solutionAmerican Regent, Inc. | 67,587.68 (Schedule G, line 22, page 12 of the filing PDF) | 98 |
| 24 | Jevtana 60 mg/1.5 mL SOLN00024582411Listed by the FDA as JevtanacabazitaxelkitSanofi-Aventis U.S. LLC | 59,606.24 (Schedule G, line 24, page 12 of the filing PDF) | 7 |
| 25 | Herceptin 150 mg SOLR50242013201Listed by the FDA as Herceptintrastuzumab150 mg/7.4 mLinjection, powder, lyophilized, for solutionGenentech, Inc. | 56,873.68 (Schedule G, line 25, page 12 of the filing PDF) | 19 |
| 26 | Imfinzi 120 mg/2.4 mL SOLN00310450012Listed by the FDA as Imfinzidurvalumab120 mg/2.4 mLinjection, solutionAstraZeneca Pharmaceuticals LP | 49,890.86 (Schedule G, line 26, page 12 of the filing PDF) | 27 |
| 27 | Kadcyla 160 mg SOLR50242008701Listed by the FDA as Kadcylaado-trastuzumab emtansine20 mg/mLinjection, powder, lyophilized, for solutionGenentech, Inc. | 45,751.12 (Schedule G, line 27, page 12 of the filing PDF) | 10 |
| 28 | Somatuline Depot 120 mg/0.5 mL SOLN15054112004Listed by the FDA as Somatuline Depotlanreotide acetate120 mg/0.5 mLinjectionIpsen Biopharmaceuticals, Inc. | 41,537.48 (Schedule G, line 28, page 12 of the filing PDF) | 12 |
| 29 | Cyramza 100 mg/10 mL SOLN00002766901Listed by the FDA as Cyramzaramucirumab10 mg/mLsolutionEli Lilly and Company | 37,929.39 (Schedule G, line 29, page 12 of the filing PDF) | 12 |
| 30 | Gamunex-C 10 g/100 mL SOLN13533080071Listed by the FDA as Gamunex-Cimmune globulin (human)10 g/100 mLinjectionGrifols USA, LLC | 36,850.00 (Schedule G, line 30, page 12 of the filing PDF) | 23 |
| 31 | Nplate 250 mcg SOLR55513022101Listed by the FDA as Nplateromiplostim250 mcg/0.5 mLinjection, powder, lyophilized, for solutionAmgen, Inc | 34,980.28 (Schedule G, line 31, page 12 of the filing PDF) | 26 |
| 32 | Retacrit 40,000 units/mL SOLN00069130904Listed by the FDA as Retacritepoetin alfa-epbx40,000 IU/mLinjection, solutionPfizer Laboratories Div Pfizer Inc | 33,526.99 (Schedule G, line 32, page 12 of the filing PDF) | 31 |
| 33 | Truxima 500 mg/50 mL SOLN63459010450Listed by the FDA as Truximarituximab-abbs10 mg/mLinjection, solutionCephalon, Inc. | 32,794.03 (Schedule G, line 33, page 12 of the filing PDF) | 23 |
| 34 | Kadcyla 100 mg SOLR50242008801Listed by the FDA as Kadcylaado-trastuzumab emtansine20 mg/mLinjection, powder, lyophilized, for solutionGenentech, Inc. | 31,479.64 (Schedule G, line 34, page 12 of the filing PDF) | 9 |
| 35 | Erbitux 200 mg/100 mL SOLN66733095823Listed by the FDA as Erbituxcetuximab2 mg/mLsolutionImClone LLC | 27,419.14 (Schedule G, line 35, page 12 of the filing PDF) | 13 |
| 36 | PACLitaxel Protein-Bound Part 100 mg SUSR00781353191Listed by the FDA as Paclitaxel100 mg/20 mLinjection, powder, lyophilized, for suspensionSandoz Inc | 24,388.82 (Schedule G, line 36, page 12 of the filing PDF) | 20 |
| 37 | Aranesp (Albumin Free) 200 mcg/0.4 mL SOSY55513002801Listed by the FDA as Aranespdarbepoetin alfa200 mcg/0.4 mLinjection, solutionAmgen, Inc | 22,614.40 (Schedule G, line 37, page 12 of the filing PDF) | 33 |
| 38 | Kyprolis 30 mg SOLR76075010201Listed by the FDA as Kyproliscarfilzomib30 mg/15 mLinjection, powder, lyophilized, for solutionOnyx Pharmaceuticals, Inc. | 19,329.46 (Schedule G, line 38, page 12 of the filing PDF) | 19 |
| 39 | Padcev 30 mg SOLR51144003001Listed by the FDA as Padcev EJFVenfortumab vedotin30 mg/3 mLinjection, powder, lyophilized, for solutionSeagen Inc. | 17,798.40 (Schedule G, line 39, page 12 of the filing PDF) | fewer than 6 (the count is not shown) |
| 40 | Padcev 20 mg SOLR51144002001Listed by the FDA as Padcev EJFVenfortumab vedotin20 mg/2 mLinjection, powder, lyophilized, for solutionSeagen Inc. | 17,797.86 (Schedule G, line 40, page 12 of the filing PDF) | 6 |
| 41 | Yondelis 1 mg SOLR59676061001Listed by the FDA as Yondelistrabectedin0.05 mg/mLinjection, powder, lyophilized, for solutionJanssen Products, LP | 16,501.68 (Schedule G, line 41, page 12 of the filing PDF) | fewer than 6 (the count is not shown) |
| 42 | Nplate 125 mcg SOLR55513022301Listed by the FDA as Nplateromiplostim125 mcg/0.25 mLinjection, powder, lyophilized, for solutionAmgen, Inc | 16,261.56 (Schedule G, line 42, page 12 of the filing PDF) | 15 |
| 43 | Neulasta Onpro 6 mg/0.6 mL SOSY55513019201Listed by the FDA as NeulastapegfilgrastimkitAmgen, Inc | 15,462.07 (Schedule G, line 43, page 12 of the filing PDF) | 46 |
| 44 | Bridion 200 mg/2 mL SOLN00006542312Listed by the FDA as Bridionsugammadex100 mg/mLinjection, solutionMerck Sharp & Dohme LLC | 15,095.86 (Schedule G, line 44, page 12 of the filing PDF) | 20 |
| 45 | Mvasi 100 mg/4 mL SOLN55513020601Listed by the FDA as Mvasibevacizumab-awwb100 mg/4 mLinjection, solutionAmgen, Inc | 15,008.28 (Schedule G, line 45, page 12 of the filing PDF) | 38 |
| 46 | Bendeka 100 mg/4 mL SOLN63459034804Listed by the FDA as Bendekabendamustine hydrochloride25 mg/mLinjection, solutionTeva Pharmaceuticals USA, Inc. | 14,727.96 (Schedule G, line 46, page 12 of the filing PDF) | 8 |
| 47 | Bendamustine HCl 100 mg/4 mL SOLN60505622800Listed by the FDA as Bendamustine Hydrochloride25 mg/mLinjection, solutionApotex Corp | 13,259.75 (Schedule G, line 47, page 12 of the filing PDF) | 9 |
| 48 | Ablysinol SOLN54288010515Listed by the FDA as Dehydrated Alcoholalcohol1 mL/mLinjection, solutionBPI Labs, LLC | 11,989.99 (Schedule G, line 48, page 12 of the filing PDF) | fewer than 6 (the count is not shown) |
| 49 | SandoSTATIN LAR Depot 30 mg KIT00078082581Listed by the FDA as Sandostatin LAR Depotoctreotide acetatekitNovartis Pharmaceuticals Corporation | 11,427.84 (Schedule G, line 49, page 12 of the filing PDF) | 7 |
| 50 | TNKase 50 mg KIT50242012047Listed by the FDA as TNKasetenecteplasekitGenentech, Inc. | 11,411.85 (Schedule G, line 50, page 12 of the filing PDF) | 6 |
| 51 | Truxima 100 mg/10 mL SOLN63459010310Listed by the FDA as Truximarituximab-abbs10 mg/mLinjection, solutionCephalon, Inc. | 10,808.69 (Schedule G, line 51, page 12 of the filing PDF) | 25 |
| 52 | Opdivo 120 mg/12 mL SOLN00003375614Listed by the FDA as Opdivonivolumab10 mg/mLinjectionE.R. Squibb & Sons, L.L.C. | 8,555.11 (Schedule G, line 52, page 12 of the filing PDF) | fewer than 6 (the count is not shown) |
| 53 | SandoSTATIN LAR Depot 20 mg KIT00078081881Listed by the FDA as Sandostatin LAR Depotoctreotide acetatekitNovartis Pharmaceuticals Corporation | 7,666.46 (Schedule G, line 53, page 12 of the filing PDF) | 10 |
| 54 | Kyprolis 10 mg SOLR76075010301Listed by the FDA as Kyproliscarfilzomib10 mg/5 mLinjection, powder, lyophilized, for solutionOnyx Pharmaceuticals, Inc. | 7,316.40 (Schedule G, line 54, page 12 of the filing PDF) | 18 |
| 55 | Abraxane 100 mg SUSR68817013450Listed by the FDA as Abraxanepaclitaxel100 mg/20 mLinjection, powder, lyophilized, for suspensionAbraxis BioScience, LLC | 7,199.22 (Schedule G, line 55, page 12 of the filing PDF) | 6 |
| 56 | Opdivo 100 mg/10 mL SOLN00003377412Listed by the FDA as Opdivonivolumab10 mg/mLinjectionE.R. Squibb & Sons, L.L.C. | 7,005.91 (Schedule G, line 56, page 13 of the filing PDF) | fewer than 6 (the count is not shown) |
| 57 | Kanjinti 150 mg SOLR55513014101Listed by the FDA as Kanjintitrastuzumab-anns150 mg/7.15 mLinjection, powder, lyophilized, for solutionAmgen, Inc | 6,666.04 (Schedule G, line 57, page 13 of the filing PDF) | 13 |
| 58 | Reblozyl 25 mg SOLR59572071101Listed by the FDA as Reblozylluspatercept25 mginjection, powder, lyophilized, for solutionCelgene Corporation | 6,074.54 (Schedule G, line 58, page 13 of the filing PDF) | fewer than 6 (the count is not shown) |
| 59 | Kedrab 1,500 units/10 mL SOLN76125015010Listed by the FDA as Kedrabhuman rabies virus immune globulin150 IU/mLinjection, solutionKedrion Biopharma Inc. | 5,539.75 (Schedule G, line 59, page 13 of the filing PDF) | fewer than 6 (the count is not shown) |
No row matches. | |||
| Total Prescription Drugs individually under $5,000 | 108,489.55 (Schedule G, row for amounts under $5,000, page 13 of the filing PDF) | 28,277 (Schedule G, claims on the row for amounts under $5,000, page 13 of the filing PDF) | |
| Total Costs of Prescription Drugs Obtained Through 340B Program Claimed for Reimbursement | 5,743,276.33 (Schedule G, printed total, page 13 of the filing PDF) | 29,401 (Schedule G, printed claims total, page 13 of the filing PDF) | |
The rows at the foot of the table are always shown. The sum above does not include them.
What “fewer than 6” means. A count of 1 to 5 is not shown on this site or in its data files. Methods, section 9, says how.
Amounts and counts are the filer’s own, in US dollars. They are written here with commas between thousands, and an amount filed with one decimal place is written with two. No value is changed: the filing and the download keep each figure as typed.
Drug names are the filer’s own words. Filers type them in many ways, so this page writes them one way: capitals, spaces, unit names such as mg and mL, a zero before a decimal point, and commas in long numbers. No word is changed, spelled out or left out, and shorthand stays as the filer typed it. The filing and the download keep each name as typed, and a search here reads both.
“Listed by the FDA as” is not part of the filing. It is the name, ingredient, strength, form and labeler that the U.S. Food and Drug Administration’s National Drug Code Directory lists for the row’s code, as downloaded on 11 November 2026. All 58 rows have one. A row has none when its code is not filed as one 11-digit code or the directory has never listed it. Where the directory has since dropped a code, the name is kept as it was last listed, and the line says so. The directory’s capitals, strengths and unit names are written one way on this page. How a code is matched
Source
- Filing PDF
- Open Schedule G on the State of Rhode Island's website
- SHA-256
- c02ed13a2319961ce259cec42fb7ca10d1db35806a6c83dcafa98df942fcb748
- Retrieved
- 11 November 2026
- Pages used
- 11 to 13 of 15